Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, ...

A research team led by Rice's Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1. ADAR1 converts adenosine to inosine in double-stranded RNA, a process essential for preventing ...

ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...

Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, ...

All starting from the same DNA, neurons ultimately take on individual characteristics in the brain and body. Differences in which genes they transcribe into RNA help determine which type of neuron ...

Korro Bio's RNA editing platform, OPERA, targets genetic diseases by performing precise, transient single-base edits on RNA, reducing the risks associated with DNA editing. Lead asset KRRO-110 aims to ...

DNA is the backbone of the genetic code so, logically, decoding and understanding the genetic sequence along with epigenetic modifications came first. Yet, RNA and the emerging field of ...

After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...

Key market opportunities in the RNA Therapy Clinical Trials sector include an increase in chronic and rare diseases, advancements in delivery technologies like lipid nanoparticles, robust venture ...